VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
P/S ratio for VolitionRx Limited (VNRX)
P/S ratio as of 2023: 65.88
According to VolitionRx Limited's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 65.88. At the end of 2022 the company had a P/S ratio of 438.98.
P/S ratio history for VolitionRx Limited from 2004 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 65.88 |
| 2022 | 438.98 |
| 2021 | 1836.39 |
| 2020 | 13112.09 |
| 2019 | 10863.06 |
| 2018 | 0.00 |
| 2017 | 0.00 |
| 2016 | 0.00 |
| 2015 | 0.00 |
| 2014 | 3543.96 |
| 2013 | 0.00 |
| 2012 | 469.97 |
| 2011 | 0.00 |
| 2010 | 0.00 |
| 2009 | 0.00 |
| 2008 | 0.00 |
| 2007 | 0.00 |
| 2006 | 0.00 |
| 2005 | 0.00 |
| 2004 | 0.00 |